What is Micronase?
Micronase was Pfizer’s brand of non-micronised glyburide, a sulfonylurea first approved in 1984 to lower blood sugar in adults with type 2 diabetes. All strengths are listed as discontinued, and generic glyburide tablets are supplied instead. Non-micronised and micronised glyburide are not bioequivalent, so anyone switching between them needs a new dose rather than a tablet-for-tablet swap. Low blood sugar remains the main risk.1
Approved products and generic therapeutic-equivalence ratings are listed in the FDA Orange Book.3
Glyburide is marketed in two forms: non-micronised tablets, the form Micronase used, and micronised tablets, the form of the discontinued Glynase brand.2
Micronised glyburide labelling reports that a lower-strength micronised tablet gave blood levels that were not bioequivalent to a higher-strength non-micronised tablet.4
The labelling for non-micronised glyburide states that people moving from other glyburide products or other oral diabetes medicines are retitrated.1
Both labellings state that there is no fixed dosage regimen for glyburide, so the dose is adjusted to each person’s blood glucose.4
Glyburide is broken down in the liver, and its metabolites are cleared roughly half in bile and half in urine, so kidney or liver insufficiency can prolong low blood sugar.1
Micronase belongs to the diabetes medicines; glipizide is another sulfonylurea.
